This article is more than 5 years old. Information may no longer be current.

EyeGate's iontophoretic contact lens receives US patent

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The United States Patent and Trademark Office has issued a patent to EyeGate Pharmaceuticals for its iontophoretic contact lens, the company announced in a press release.

The patent, the first covering the iontophoretic contact lens, is for a multi-layer contact lens for ocular therapy. It has a reservoir with an electrically charged therapeutic compound and an electrode that provides an iontophoretic current to the charged compound to propel it into ocular tissue, the release said.

“We believe this technology, which could enable at-home administration of iontophoretic drugs, has the potential to significantly influence the future of ocular drug delivery by eliminating the need for intravitreal injections and reducing the number of doctor visits,” Stephen From, EyeGate president and CEO, said in the release. “We believe that the iontophoretic contact lens is particularly well-suited for the treatment of chronic retinal conditions and have selected macular edema, which we believe is a large and underserved market, as our initial target indication.”